Loading...
01/11 15:18
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents a mixed picture. Strong revenue growth and optimistic guidance for 2025 are positives. However, challenges like Epicel revenue variability, increased operating expenses, and lack of shareholder return plans are concerning. The Q&A revealed uncertainties about MACI Arthro's impact and market expansion, contributing to a neutral sentiment. Without a market cap, stock volatility cannot be precisely gauged, but the absence of significant catalysts suggests a neutral outlook in the short term.
Total Net Revenue $52.6 million, representing a year-over-year increase of 22%.
MACI Revenue $46.3 million, with a 15% year-over-year growth, adjusted for one fewer selling day represents approximately 17% growth.
Epicel Revenue $5 million, lower than anticipated due to a high percentage of canceled orders related to patient health issues.
NexoBrid Revenue $1.3 million, representing a 207% year-over-year growth and a 31% sequential growth.
Gross Profit $36.3 million, maintaining a gross margin of 69%, consistent with the prior year.
Operating Expenses $49.1 million, an increase from $40.8 million in the same period last year, primarily due to increased headcount and costs related to the new facility.
Net Loss $11.2 million or $0.23 per share.
Non-GAAP Adjusted EBITDA $3.2 million, or 6% of net revenue.
Operating Cash Flow $6.6 million.
Cash Position Approximately $162 million in cash, restricted cash, and investments, with no debt.
MACI Revenue: Record first quarter revenue of more than $46 million, driven by strong underlying fundamentals and expansion of the MACI surgeon customer base.
NexoBrid Revenue: First quarter revenue increased over 200% compared to last year, indicating strong growth and progress in the NexoBrid launch.
MACI Arthro Launch: Significant strength in leading performance indicators with approximately 400 MACI Arthro surgeons trained, ahead of the pace from the initial MACI launch.
MACI Ankle Development Program: On track to initiate Phase III Mascot clinical study in the second half of the year, representing a potential $1 billion addressable market.
Total Revenue Growth: Expecting total company revenue growth of 22% to 25% for Q2 2025, with full year guidance maintained at 20% to 23%.
Epicel Performance: Stronger Epicel performance expected in Q2, with grafts from cases completed or scheduled exceeding total graft volume in Q1.
Operating Cash Flow: Generated $6.6 million of operating cash flow and ended the quarter with approximately $162 million in cash, restricted cash, and investments.
Sales Force Expansion: Plans to begin MACI sales force expansion in the second half of the year.
Profitability Guidance: Raising gross margin guidance to 75% and adjusted EBITDA margin guidance to 26% for the full year.
Market Positioning: Positioned for strong revenue and profit growth in 2025, with significant strength in MACI business fundamentals and improved trends for Epicel.
Epicel Revenue Variability: Epicel revenue was lower than anticipated due to a high percentage of canceled orders related to patient health issues, indicating unpredictability in revenue generation.
Regulatory and Market Variability: The nature of the burn care market makes it difficult to predict the cadence of Epicel quarterly revenue, demonstrating significant variability in patient health and treatment timing.
Supply Chain and Tariff Impact: While the company anticipates minimal impact from tariffs due to domestic manufacturing and safety stock, any future tariffs on pharmaceuticals could still pose a risk to cost of goods sold and gross margins.
Operational Challenges: Increased operating expenses due to headcount growth and new facility costs may impact profitability, despite expectations for improved margins in subsequent quarters.
Market Competition: The company faces competitive pressures in the MACI market, particularly as it expands into new segments and develops new products like MACI Arthro.
MACI Revenue Growth: Expecting MACI revenue growth of approximately 22% to 24% for Q2 2025, with record first quarter revenue of more than $46 million.
NexoBrid Revenue Growth: NexoBrid first quarter revenue increased over 200% compared to last year, with a focus on deeper penetration across ordering centers.
MACI Ankle Development Program: Advancing the MACI Ankle Development Program, with plans to initiate Phase III Mascot clinical study in the second half of 2025.
MACI Sales Force Expansion: Plans to begin MACI sales force expansion in the second half of 2025.
Q2 2025 Revenue Guidance: Expecting total revenue growth in the 22% to 25% range, approximately $64 million to $66 million.
Full Year 2025 Revenue Guidance: Maintaining total revenue growth guidance of 20% to 23%.
Profitability Guidance: Raising gross margin guidance to 75% and adjusted EBITDA margin guidance to 26% for the full year.
Long-term Profitability Goals: Targeting high 70% gross margin and high 30% adjusted EBITDA margin by 2029.
Shareholder Return Plan: The company has not announced any share buyback program or dividend program during the call.
The earnings call highlights strong financial performance, with record high operating cash flow and free cash flow, along with positive trends in MACI Arthro demand and surgeon adoption. The Q&A session reveals positive analyst sentiment, with no significant insurance challenges reported. The company's MACI sales force expansion and expected profitability improvements further support a positive outlook. However, cautious guidance for Q4 and lack of specific 2026 projections slightly temper enthusiasm. Overall, the sentiment is positive, with potential for a stock price increase in the 2% to 8% range.
The earnings call shows strong financial performance with record revenue growth and narrowed net loss, despite a slight miss in MACI's Q2 guidance. Optimistic guidance and improvements in profitability metrics, along with strategic expansions in sales force and international markets, suggest positive sentiment. The Q&A section highlights potential risks but also reinforces confidence in future growth, particularly in MACI and NexoBrid segments. Overall, the positive aspects outweigh the negatives, suggesting a likely stock price increase.
The earnings call presents mixed signals: strong revenue growth and promising product developments are offset by missed EPS expectations, increased operating expenses, and revenue variability in key areas like Epicel. The Q&A section reveals some optimism, but also highlights uncertainties regarding MACI Arthro's impact and competitive pressures. The lack of a share repurchase program further tempers positive sentiment. Given these factors, the stock price is likely to remain stable, with no significant movement expected over the next two weeks.
The earnings call presents a mixed picture. Strong revenue growth and optimistic guidance for 2025 are positives. However, challenges like Epicel revenue variability, increased operating expenses, and lack of shareholder return plans are concerning. The Q&A revealed uncertainties about MACI Arthro's impact and market expansion, contributing to a neutral sentiment. Without a market cap, stock volatility cannot be precisely gauged, but the absence of significant catalysts suggests a neutral outlook in the short term.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
